Evidence map›Paper›PMID 32532251›Full record

ArticleBMC neurology2020

Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients.

Pabitra Basnyat, Marko Pesu, Mikael Söderqvist, Anna Grönholm, Suvi Liimatainen, Maria Peltola, Jani Raitanen, Jukka Peltola

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Interleukins in Epilepsy: Friend or Foe.Neuroscience bulletin · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. GABAScientific reports · 2022
    Article
  9. Blood biomarkers in epilepsy.Acta neurologica Scandinavica · 2022
    Review
  10. Article
  11. Evaluation of IL-10, IFN-γ, and thiol-disulfide homeostasis in patients with drug-resistant epilepsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Pabitra BasnyatDepartment of Neurology, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, D532, 33520, Tampere, Finland. pabitra.basnyat@tuni.fi.ORCID http://orcid.org/0000-0002-2239-7681
Marko PesuImmunoregulation, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Mikael SöderqvistDepartment of Neurology, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, D532, 33520, Tampere, Finland.
Anna GrönholmImmunoregulation, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Suvi LiimatainenDepartment of Neurology, Tampere University Hospital, Tampere, Finland.
Maria PeltolaDepartment of Child Psychiatry, Tampere University Hospital, Tampere, Finland.
Jani RaitanenFaculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland.
Jukka PeltolaDepartment of Neurology, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, D532, 33520, Tampere, Finland.
Tampere University · FITampere University Hospital · FITampere University of Applied Sciences · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing evidence supports the role of soluble inflammatory mediators in the pathogenesis of refractory temporal lobe epilepsy (TLE). Hippocampal sclerosis (HS) is a well-described pathohistological abnormality in TLE. The association of proinflammatory cytokines with epileptic disease profiles is well established; however, the potential significance of circulating interleukin 10 (IL-10), particularly in TLE-associated HS, is still poorly understood. Therefore, taking into consideration the neuroprotective and anticonvulsive effects of IL-10, we performed this study to examine the role of the plasma levels of IL-10 in patients with TLE with HS (TLE + HS), TLE without HS (TLE-HS) and with other types of epilepsy.

methodsThis study included 270 patients with refractory epilepsy who were classified into four groups: i) 34 patients with TLE + HS, ii) 105 patients with TLE-HS, iii) 95 patients with extra-TLE (XLE) and iv) 36 patients with idiopathic generalized epilepsy (IGE). The plasma IL-10 levels were quantified using a commercially available enzyme-linked immunosorbent assay (ELISA).

resultsIL-10 levels were significantly lower in TLE + HS than in TLE-HS (p = 0.013). In a subgroup of TLE-HS patients who had seizures 1 month before sampling, patients with seizures had significantly higher IL-10 levels than patients who were seizure-free (p = 0.039). Among a small group (n = 15) of non-refractory TLE-HS patients, IL-10 levels showed a moderate negative correlation with the duration of epilepsy (r = - 0.585, p = 0.023).

conclusionsThis study demonstrated that chronically reduced levels of plasma IL-10 were associated with HS in TLE patients, suggesting that there was an inadequate systemic anti-inflammatory immune response. These results could provide new biological insights into the pathophysiology of HS in TLE. We also found that the production of IL-10 could be affected by the seizure frequency and declined concomitantly with increased disease durations. Therefore, the measurement of plasma IL-10 may have diagnostic value as a biomarker for stratifying TLE + HS from other epilepsy types or as a marker of disease progression towards a progressive form of epilepsy.

Indexed as

AdultDrug Resistant EpilepsyEpilepsy, Temporal LobeFemaleHippocampusHumansInterleukin-10MaleMiddle AgedSclerosisIL10 protein, humanInterleukin-10EpilepsyHippocampal sclerosisInterleukin 10 (IL-10)RefractorySeizuresTemporal lobe

Identifiers

PMID32532251
PMCPMC7291453
OpenAlexW3035334811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.